

Data Supplement for Fornaro et al., Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. *Am J Psychiatry* (doi: 10.1176/appi.ajp.2019.19030228)

**TABLE S1.** List of studies excluded after full-text assessment

<b>Authors, year</b>	<b>Reason for exclusion</b>
(Poornima Rao, Rajpal, Bali, & Kau, 2018)	Case report
(Zamani, Paezi, & Hassanian-Moghaddam, 2017)	Case report
(Heller et al., 2017)	No data on lithium safety or efficacy
(Kieviet, de Jong, Scheele, Dolman, & Honig, 2017)	No data on lithium safety or efficacy
(Nishigori et al., 2017)	No data on lithium safety or efficacy
(Develin, 2017; Uguz, 2017)	No data on lithium safety or efficacy
(Uguz, 2017)	No data on lithium safety or efficacy
(Chigome et al., 2017)	No data on lithium safety or efficacy
(Boden et al., 2012)	No data on lithium safety or efficacy
(Kallen & Reis, 2012)	No data on lithium safety or efficacy
(Petersen et al., 2016)	No data on lithium safety or efficacy
(Wesseloo et al., 2017)	No data on lithium safety or efficacy
(Westin et al., 2017)	No data on lithium safety or efficacy
(Broeks, Thisted Horsdal, Glejsted Ingstrup, & Gasse, 2017)	No data on lithium safety or efficacy
(Leong et al., 2017)	No data on lithium safety or efficacy
(Michielsen, van der Heijden, Janssen, & Kuijpers, 2014)	No data on lithium safety or efficacy
(Sebela, Noskova, Goetz, & Mohr, 2017)	Not in English (Czech)
(Kerremans, 2017)	Not in English (Dutch)
(Prieto et al., 2018)	Not in English (Spanish)
(Umylny, German, & Lantiere, 2017)	Review
(Howdeshell & Ornoy, 2017)	Review
(Sani, Perugi, & Tondo, 2017)	Review
(Ornoy, Weinstein-Fudim, & Ergaz, 2017)	Review
(Thomson & Sharma, 2018)	Review
(Parker, Graham, & Tavella, 2017)	Review
(Thomson & Sharma, 2017)	Review
(Graham, Tavella, & Parker, 2018)	Review
(Scrandis, 2017)	Review
(Haskey & Galbally, 2017)	Review
(Aftab & Shah, 2017)	Review
(Sharma, Doobay, & Baczynski, 2017)	Review
(Smith & Dubovsky, 2017)	Review
(Jones & Jones, 2017)	Review

## References (excluded articles)

- Aftab, A., & Shah, A. A. (2017). Behavioral Emergencies: Special Considerations in the Pregnant Patient. *Psychiatr Clin North Am*, 40(3), 435-448. doi:10.1016/j.psc.2017.05.017
- Boden, R., Lundgren, M., Brandt, L., Reutfors, J., Andersen, M., & Kieler, H. (2012). Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. *BMJ*, 345, e7085. doi:10.1136/bmj.e7085
- Broeks, S. C., Thisted Horsdal, H., Glejsted Ingstrup, K., & Gasse, C. (2017). Psychopharmacological drug utilization patterns in pregnant women with bipolar disorder - A nationwide register-based study. *J Affect Disord*, 210, 158-165. doi:10.1016/j.jad.2016.12.001
- Chigome, A., Matsangaise, M., Chukwu, B., Matlala, M., Sibanda, M., & Meyer, J. (2017). Review of selective serotonin reuptake inhibitors. *SA Pharmaceutical Journal*.(84 (6) ), 52-59.
- Develin, A. (2017). Medicines toxicity and the core skills of a pharmacist. *Australian Journal of Pharmacy*.(98 (1168)), 70-77.
- Graham, R. K., Tavella, G., & Parker, G. B. (2018). Is there consensus across international evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period? *J Affect Disord*, 228, 216-221. doi:10.1016/j.jad.2017.12.022
- Haskey, C., & Galbally, M. (2017). Mood stabilizers in pregnancy and child developmental outcomes: A systematic review. *Aust N Z J Psychiatry*, 51(11), 1087-1097. doi:10.1177/0004867417726175
- Heller, H., Ravelli, A., Bruning, A., de Groot, C., Scheele, F., van Pampus, M., & Honig, A. (2017). Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: A matched cohort study. *BMC Pregnancy and Childbirth*. 17 (1).
- Howdeshell, K. L., & Ornoy, A. (2017). Depression and Its Treatment During Pregnancy: Overview and Highlights. *Birth Defects Res*, 109(12), 877-878. doi:10.1002/bdr2.1080
- Jones, S. C., & Jones, I. (2017). Pharmacological Management of Bipolar Disorder in Pregnancy. *CNS Drugs*, 31(9), 737-745. doi:10.1007/s40263-017-0452-x
- Kallen, B., & Reis, M. (2012). Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. *J Clin Psychopharmacol*, 32(5), 608-614. doi:10.1097/JCP.0b013e3182668568
- Kerremans, A. (2017). Lithium and pregnancy. *Geneesmiddelenbulletin*(51 (11) ), 91-92.
- Kieviet, N., de Jong, F., Scheele, F., Dolman, K. M., & Honig, A. (2017). Use of antidepressants during pregnancy in the Netherlands: observational study into postpartum interventions. *BMC Pregnancy Childbirth*, 17(1), 23. doi:10.1186/s12884-016-1184-5
- Leong, C., Raymond, C., Chateau, D., Dahl, M., Alessi-Severini, S., Falk, J., . . . Katz, A. (2017). Psychotropic Drug Use before, during, and after Pregnancy: A Population-Based Study in a Canadian Cohort (2001-2013). *Can J Psychiatry*, 62(8), 543-550. doi:10.1177/0706743717711168
- Michielsen, L. A., van der Heijden, F. M., Janssen, P. K., & Kuijpers, H. J. (2014). Effects of maternal psychotropic drug dosage on birth outcomes. *Neuropsychiatr Dis Treat*, 10, 13-18. doi:10.2147/NDT.S53430
- Nishigori, H., Obara, T., Nishigori, T., Mizuno, S., Metoki, H., Hoshiai, T., . . . Children's Study, G. (2017). Selective serotonin reuptake inhibitors and risk of major congenital anomalies for pregnancies in Japan: A nationwide birth cohort study of the Japan Environment and Children's Study. *Congenit Anom (Kyoto)*, 57(3), 72-78. doi:10.1111/cga.12202
- Ornoy, A., Weinstein-Fudim, L., & Ergaz, Z. (2017). Antidepressants, Antipsychotics, and Mood Stabilizers in Pregnancy: What Do We Know and How Should We Treat Pregnant Women with Depression. *Birth Defects Res*, 109(12), 933-956. doi:10.1002/bdr2.1079

- Parker, G. B., Graham, R. K., & Tavella, G. (2017). Is there consensus across international evidence-based guidelines for the management of bipolar disorder? *Acta Psychiatr Scand*, *135*(6), 515-526. doi:10.1111/acps.12717
- Petersen, I., McCrear, R. L., Sammon, C. J., Osborn, D. P., Evans, S. J., Cowen, P. J., . . . Nazareth, I. (2016). Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. *Health Technol Assess*, *20*(23), 1-176. doi:10.3310/hta20230
- Poornima Rao, S., Rajpal, N., Bali, S., & Kau, N. (2018). Bipolar affective disorder and wilson's disease: Case report and review of literature. *Indian Journal of Psychiatry. Conference: 70th Annual National Conference of Indian Psychiatric Society, ANCIPS 2018. India., 60* (5 Supplement 1) S151.
- Prieto, M., Oraa, R., Zardoya, M., Uriarte, J., Malo, P., Medrano, J., & Pacheco, L. (2018). The use of mood regulators in pregnancy and breastfeeding. *Psiquiatria Biologica*.
- Sani, G., Perugi, G., & Tondo, L. (2017). Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice? *Clin Drug Investig*, *37*(8), 713-727. doi:10.1007/s40261-017-0531-2
- Scrandis, D. A. (2017). Bipolar Disorder in Pregnancy: A Review of Pregnancy Outcomes. *J Midwifery Womens Health*, *62*(6), 673-683. doi:10.1111/jmwh.12645
- Sebela, A., Noskova, E., Goetz, M., & Mohr, P. (2017). Psychotropic drugs in pregnancy - do they reduce or increase the risks for the fetus? Part two: Mood stabilizers, anxiolytics. *Pediatric pro Praxi*.(18 (6)), 352-355.
- Sharma, V., Doobay, M., & Baczynski, C. (2017). Bipolar postpartum depression: An update and recommendations. *J Affect Disord*, *219*, 105-111. doi:10.1016/j.jad.2017.05.014
- Smith, B., & Dubovsky, S. L. (2017). Pharmacotherapy of mood disorders and psychosis in pre- and post-natal women. *Expert Opin Pharmacother*, *18*(16), 1703-1719. doi:10.1080/14656566.2017.1391789
- Thomson, M., & Sharma, V. (2017). Between a rock-a-bye and a hard place: mood disorders during the peripartum period. *CNS Spectr*, *22*(S1), 49-64. doi:10.1017/S1092852917000852
- Thomson, M., & Sharma, V. (2018). Weighing the Risks: the Management of Bipolar Disorder During Pregnancy. *Curr Psychiatry Rep*, *20*(3), 20. doi:10.1007/s11920-018-0882-2
- Uguz, F. (2017). Prophylactic use of olanzapine and quetiapine from pregnancy to the postpartum period in women with bipolar disorder: a case series. *J Matern Fetal Neonatal Med*, *30*(21), 2569-2571. doi:10.1080/14767058.2016.1256991
- Umylny, P., German, M., & Lantiere, A. (2017). Treating postpartum mood and anxiety disorders in primary care pediatrics. *Curr Probl Pediatr Adolesc Health Care*, *47*(10), 254-266. doi:10.1016/j.cppeds.2017.08.003
- Wesseloo, R., Wierdsma, A. I., van Kamp, I. L., Munk-Olsen, T., Hoogendijk, W. J. G., Kushner, S. A., & Bergink, V. (2017). Lithium dosing strategies during pregnancy and the postpartum period. *Br J Psychiatry*, *211*(1), 31-36. doi:10.1192/bjp.bp.116.192799
- Westin, A. A., Brekke, M., Molden, E., Skogvoll, E., Aadal, M., & Spigset, O. (2017). Changes in drug disposition of lithium during pregnancy: a retrospective observational study of patient data from two routine therapeutic drug monitoring services in Norway. *BMJ Open*, *7*(3), e015738. doi:10.1136/bmjopen-2016-015738
- Zamani, N., Paezi, M., & Hassanian-Moghaddam, H. (2017). Lithium Toxicity in a Pregnant Woman. *Basic Clin Pharmacol Toxicol*, *120*(5), 509-511. doi:10.1111/bcpt.12747

**TABLE S2.** Quality assessment of the included studies

		NEWCASTLE-OTTAWA SCALE CASE-CONTROL STUDIES ( <a href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp">http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</a> )									
<i>Author</i>	<i>Year</i>	<i>Selection—Case definition</i>	<i>Selection—Representativeness of the cases</i>	<i>Selection—Selection of controls</i>	<i>Selection—Definition of controls</i>	<i>Comparability of cases and controls</i>	<i>Exposure—Ascertainment of exposure</i>	<i>Exposure—Nonresponse rate</i>		<i>Quality rating</i>	
Edmonds	1990	*	*	*	*	*	*	*		Good	
Zalztein	1990	*	*	*	*	*	-	-		Good	
Czeizel	1990	*	*	*	*	**	*	*		Good	
Lisi	2010	*	*	*	*	**	*	*		Good	
Boyle	2016	*	*	*	*	**	*	*		Good	
		NEWCASTLE-OTTAWA SCALE COHORT STUDIES ( <a href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp">http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</a> )									
<i>Author</i>	<i>Year</i>	<i>Selection—Representativeness of exposed cohort</i>	<i>Selection—Representativeness of the unexposed cohort</i>	<i>Selection—Ascertainment of exposure</i>	<i>Selection—Demonstration, outcome of the study, was not present at the beginning of the study</i>	<i>Comparability of cohorts</i>	<i>Outcome—Assessment of outcome</i>	<i>Outcome—Follow-up long enough</i>	<i>Outcome—Adequacy of follow-up cohorts</i>	<i>Quality rating</i>	
<b>Prospective cohort</b>											
Schou	1976	*	-	-	-	-	-	*	*	Poor	
Jacobson	1992	*	*	*	*	*	*	*	*	Good	
Diav-citrin	2014	*	*	*	*	*	*	*	*	Good	
Newport	2005	-	-	*	*	*	*	*	*	Poor	
<b>Retrospective cohort</b>											
Schou	1973	-	-	*	*	*	*	*	*	Poor	
Weinstein	1975	*	-	-	*	-	*	*	*	Poor	
Weinstein	1976	*	-	-	*	-	*	*	*	Poor	
Kallen	1983	*	*	*	*	*	*	*	*	Good	
Troyer	1993	*	*	*	*	*	*	*	*	Good	
		<i>Selection—Representativeness of exposed cohort</i>	<i>Selection—Representativeness of the unexposed cohort</i>	<i>Selection—Ascertainment of exposure</i>	<i>Selection—Demonstration, outcome of the study was not present at the beginning of the study</i>	<i>Comparability of cohorts</i>	<i>Outcome—Assessment of outcome</i>	<i>Outcome—Follow-up long enough</i>	<i>Outcome—Adequacy of follow-up cohorts</i>	<i>Quality rating</i>	
Kallen	2012	*	*	*	*	*	*	*	*	Good	
Van der Lugt	2012	-	-	*	*	-	*	*	*	Poor	

(Continued)

Table S2 Continued

Wesseloo R.	2017	*	*	*	*	*	*	*	*	Good
Forsberg L	2017	*	*	*	*	*	*	*	*	Good
Patomo E.	2017	*	*	*	*	*	*	*	*	Good
Frayne J.	2017	*	*	*	*	**	*	*	*	Good
Munk-Olsen T. (six international studies)	2018	*	*	*	*	**	*	*	*	Good
<b>COCHRANE RISK OF BIAS TOOL FOR RANDOMIZED CONTROLLED TRIALS</b>										
<a href="http://methods.cochrane.org/bias/sites/methods.cochrane.org.bias/files/public/uploads/6.%20Assessing%20risk%20of%20bias%20in%20included%20studies%20v1.0%20Standard%20author%20slides.pdf">http://methods.cochrane.org/bias/sites/methods.cochrane.org.bias/files/public/uploads/6.%20Assessing%20risk%20of%20bias%20in%20included%20studies%20v1.0%20Standard%20author%20slides.pdf</a>										
<b>Author</b>	<b>Year</b>	<b>Random sequence generation</b>	<b>Allocation concealment</b>	<b>Blinding of participants</b>	<b>Blinding of evaluator (self-reported)</b>	<b>Blinding of evaluator (objective measures)</b>	<b>Incomplete outcome data</b>	<b>Selective reporting</b>	<b>Other bias</b>	<b>Overall</b>
Austin	1992	Unclear	High risk	High risk	High risk	High risk	Low risk	Low risk	-	High
Bergink	2012	Unclear	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	-	Unclear
Rosso	2016	High	High	High	Unclear	Unclear	Low risk	Low risk	Selection bias	High